Studies related to Anti-Oxidant Enzyme Profile and Vitamin B2

Riboflavin Supplementation To Patients With Multiple Sclerosis Does Not Improve Disability Status Nor Is Riboflavin Supplementation Correlated To Homocysteine

Effect None
Trial Design Double blind
Trial Length 6+ Months
Number of Subjects 29
Sex Both Genders
Age Range 30-44
Notes for this study:
Supplementation of 10mg riboflavin daily over the course of six months in subjects with multiple sclerosis failed to influence the disease state any differently than placebo (both groups experienced benefit) and also failed to have an influence on homocysteine concentrations in serum or glutathione reductase activity in red blood cells.